Bastrop, TX, Aug 14, 2018

Caligor Coghlan, a leading biopharmaceutical services company providing global clinical trial material management, supply solutions and expanded access program management, today announced the appointment of Lisa Rich-Milan as Chief Executive Officer.

“Lisa’s deep industry expertise and experience in a range of mission-critical roles effectively position her to lead Caligor Coghlan as we deliver global services to our clients and continue to identify innovative ways to exceed expectations,” said Kevin Ma, current Chairman of the Board of Directors. “We are extremely excited to welcome Lisa as CEO.”

Ms. Rich-Milan has more than twenty-five years of executive-level experience in pharmaceuticals, biotechnology, generics and diagnostics in a wide range of therapeutic areas including oncology, cardiovascular and CNS. Most recently, she led the national commercial teams for Quest Clinical Informatics and served as CEO for CompuNet Clinical Laboratory, a joint venture with Quest Diagnostics. Prior to Quest, she held senior leadership roles in which she led clinical trials and alliance partnerships as well as sales, marketing, operations and payer teams at companies including Bristol-Myers Squibb, UCB, Synthon Pharmaceuticals and Roche Diagnostics.

“The biopharmaceutical industry has relied on Caligor Coghlan for many years to help safeguard the progress of clinical trials,” noted Ms. Rich-Milan. “Similarly, the company is entrusted to manage expanded access programs which are vital to patients and physicians in need of new treatment options. I step into the role of CEO with a commitment to our clients and employees to continue an unmatched level of quality, service and counsel in these important areas.”

About Caligor Coghlan
Caligor Coghlan provides global clinical trial material management, supply solutions and expanded access program management to the biopharmaceutical industry. The company solves complex supply chain challenges, helping to ensure clinical trials remain safe, efficient and on schedule. Services include commercial drug sourcing (comparators, standard of care therapies, rescue medicines, devices, ancillaries, etc.), secondary packaging, labeling, placebo manufacturing, blinding, returns, and destruction of clinical trial material as well as worldwide distribution (including direct-to-depot, direct-to-site and direct-to-patient capabilities). Caligor Coghlan operates facilities in Bastrop, TX and Dartford, UK and maintains a global network of depots to ensure rapid and timely delivery of clinical trial supplies and therapeutics to patients and physicians.

Media Contact:
AP Communications
Amy Phillips